Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898483 | 1.00 | FASN (0.53) | FASNMEN1LMNATP53MAPT | |
| SCHEMBL30550426 | 0.90 | FASN (0.44) | FASNMEN1LMNATP53MAPT | |
| SCHEMBL31578852 | 0.87 | FASN (0.69) | FASNMEN1LMNAKMT2APLA2G2A | |
| SCHEMBL30550308 | 0.87 | FASN (0.69) | FASNMEN1LMNAKMT2APLA2G2A | |
| SCHEMBL31289413 | 0.86 | LMNA (0.43) | FASNMEN1LMNATP53MAPT | |
| SCHEMBL31232358 | 0.83 | FASN (0.50) | FASNLMNAPLA2G2AFFAR1PLA2G5 | |
| SCHEMBL30550440 | 0.83 | FASN (0.50) | FASNLMNAPLA2G2AFFAR1PLA2G5 | |
| SCHEMBL34468665 | 0.82 | FASN (0.49) | FASNPLA2G2A | |
| SCHEMBL34468645 | 0.81 | FASN (0.51) | FASNPLA2G2AFFAR1 | |
| SCHEMBL31232367 | 0.81 | FASN (0.59) | FASNMEN1LMNAKMT2APLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887658-A | Method for differentiating human pluripotent stem cells into natural killer cells and application thereof | 浙江霍德生物工程有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20260115152-A1 | AGRIMOL B DERIVATIVES AND METHODS OF MAKING AND USE THEREOF | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260115152-A1 | AGRIMOL B DERIVATIVES AND METHODS OF MAKING AND USE THEREOF | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260115152-A1 | AGRIMOL B DERIVATIVES AND METHODS OF MAKING AND USE THEREOF | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2026-04-30 | — | — | US | disclosed |
| CN-121925254-A | Oral composition, method for masking bitterness of oral composition, and method for producing oral composition | 株式会社芳珂 | 2026-04-24 | — | — | CN | disclosed |
| JP-2025116270-A | INHIBITION OF MUSCLE ATROPHY | 株式会社ファンケル | 2025-08-07 | — | — | JP | disclosed |
| US-20250162973-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | University of Hong Kong Versitech Limited (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20250162973-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | University of Hong Kong Versitech Limited (CN) | 2025-05-22 | — | — | US | disclosed |
| JP-2025001603-A | ORAL COMPOSITION, METHOD FOR MASKING BITTERNESS IN ORAL COMPOSITION, AND METHOD FOR PRODUCING ORAL COMPOSITION | 株式会社ファンケル | 2025-01-08 | — | — | JP | disclosed |
| WO-2024262570-A1 | ORAL COMPOSITION, METHOD FOR MASKING BITTERNESS IN ORAL COMPOSITION, AND METHOD FOR PRODUCING ORAL COMPOSITION | 株式会社ファンケル | 2024-12-26 | — | — | WO | disclosed |
| CN-116440106-B | Application of agrimophol B in preparing medicament for treating hepatocellular carcinoma and medicament thereof | 四川大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-117887658-A | Method for differentiating human pluripotent stem cells into natural killer cells and application thereof | 浙江霍德生物工程有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023160543-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | VERSITECH LIMITED (CN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023160543-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | VERSITECH LIMITED (CN) | 2023-08-31 | — | — | WO | disclosed |
| CN-116440106-A | Application of agrimophol B in preparing medicament for treating hepatocellular carcinoma and medicament thereof | 四川大学 | 2023-07-18 | — | — | CN | disclosed |
| JP-2023044668-A | Anti-aging composition | 株式会社ファンケル | 2023-03-30 | — | — | JP | disclosed |
| JP-2022187483-A | AUTOPHAGY PROMOTING COMPOSITION | 株式会社ファンケル | 2022-12-19 | — | — | JP | disclosed |
| JP-2022167403-A | Inhibition of muscle atrophy | 株式会社ファンケル | 2022-11-04 | — | — | JP | disclosed |
| JP-2022093894-A | Immunostimulatory composition | 株式会社ファンケル | 2022-06-24 | — | — | JP | disclosed |
| JP-2022093893-A | ANTIALLERGIC COMPOSITION | 株式会社ファンケル | 2022-06-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250162973-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | GOLIM4, GOLT1B, GOLGA2 | FASN 1842/4885MEN1 2581/4885LMNA 3326/4885 |
| US-20260115152-A1 | AGRIMOL B DERIVATIVES AND METHODS OF MAKING AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AR, MCL1 | FASN 2296/4885MEN1 3965/4885LMNA 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.